Using small molecule libraries and high throughput screening to identify new inhibitory compounds to manage mucoepidermoid carcinomas from the salivary glands

Abstract

Mucoepidermoid carcinoma (MEC) is the most common malignancy from the salivary glands. The management of MEC follows similar protocols used in other malignancies from the salivary glands. Our previous results presented new therapies that target cancer stem cells (CSC) from MEC. However, new approaches are needed due to radiotherapy toxicities and resistance against the current chemotherapy (Cisplatin), found mainly by CSC. Recently, we demonstrated that epigenetic events have been shown to play an important role in MEC behavior. Based on the current lack of a therapy developed exclusively for MEC, we are proposing to evaluate an Epigenetics Compound Library ("epi-drugs") to identify new pharmacological agents capable of impacting the growth of MEC. Here, we will investigate the "epi-drugs" in 2D and 3D culture models, by High-precision liquid handler and high-throughput assays. Proliferation, migration, and tumorspheres will be evaluated by functional assays. We expect to identify active molecules and define the target population that will most likely benefit from the therapy. (AU)